VFA
AEGR

Virtus Fund Advisers’s Aegerion Pharmaceuticals AEGR Stock Holding History

Virtus Fund Advisers’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,515
Closed -$81K – 2485
2014
Q2 		$81K Buy
+2,515
New +$93.6K ﹤0.01% 1548

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus Fund Advisers's AEGR Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2014, closing a stake of 2,515 shares — an estimated $81K sold.

Virtus Fund Advisers first reported a position in AEGR in Q2 2014 and held it in 1 quarter. The position peaked at $81K in Q2 2014. 131 funds tracked by Wall St. Rank hold AEGR as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Aegerion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 2,515 Aegerion Pharmaceuticals shares in Q3 2014, an estimated $81K.
  • Virtus Fund Advisers first reported a position in Aegerion Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Aegerion Pharmaceuticals position peaked at $81K in Q2 2014.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.